322 related articles for article (PubMed ID: 33054820)
41. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
[TBL] [Abstract][Full Text] [Related]
42. Implications of bilateral free trade agreements on access to medicines.
Correa CM
Bull World Health Organ; 2006 May; 84(5):399-404. PubMed ID: 16710551
[TBL] [Abstract][Full Text] [Related]
43. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
44. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
Godman B; Hill A; Simoens S; Selke G; Selke Krulichová I; Zampirolli Dias C; Martin AP; Oortwijn W; Timoney A; Gustafsson LL; Voncina L; Kwon HY; Gulbinovic J; Gotham D; Wale J; Cristina Da Silva W; Bochenek T; Allocati E; Kurdi A; Ogunleye OO; Meyer JC; Hoxha I; Malaj A; Hierländer C; Sauermann R; Hamelinck W; Petrova G; Laius O; Langner I; Yfantopoulos J; Joppi R; Jakupi A; Greiciute-Kuprijanov I; Vella Bonanno P; Piepenbrink JH; de Valk V; Wladysiuk M; Marković-Peković V; Mardare I; Fürst J; Tomek D; Obach Cortadellas M; Zara C; Pontes C; McTaggart S; Laba TL; Melien Ø; Wong-Rieger D; Bae S; Hill R
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):527-540. PubMed ID: 33535841
[No Abstract] [Full Text] [Related]
45. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
Hu J; Mossialos E
Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
[TBL] [Abstract][Full Text] [Related]
46. Trade agreements and the risks for the nursing workforce, nursing practice and public health: A scoping review.
Kidgell D; Hills D; Griffiths D; Endacott R
Int J Nurs Stud; 2020 Sep; 109():103676. PubMed ID: 32603925
[TBL] [Abstract][Full Text] [Related]
47. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
Faunce TS; Tomossy GF
Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881
[TBL] [Abstract][Full Text] [Related]
48. A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges.
Vella Bonanno P; Cassar V; Godman B
Front Pharmacol; 2021; 12():666405. PubMed ID: 34867312
[TBL] [Abstract][Full Text] [Related]
49. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
Allard Soto R
Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
[TBL] [Abstract][Full Text] [Related]
50. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
[TBL] [Abstract][Full Text] [Related]
51. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
[TBL] [Abstract][Full Text] [Related]
52. Policy space for health and trade and investment agreements.
Koivusalo M
Health Promot Int; 2014 Jun; 29 Suppl 1():i29-47. PubMed ID: 25217355
[TBL] [Abstract][Full Text] [Related]
53. Trade agreements, intellectual property, and the role of the World Bank in improving access to medicines in developing countries.
Rovira J
Yale J Health Policy Law Ethics; 2004; 4(2):401-13. PubMed ID: 15536921
[No Abstract] [Full Text] [Related]
54. International Experience in Therapeutic Value and Value-Based Pricing: A Rapid Review of the Literature.
Prieto-Pinto L; Garzón-Orjuela N; Lasalvia P; Castañeda-Cardona C; Rosselli D
Value Health Reg Issues; 2020 Dec; 23():37-48. PubMed ID: 32688214
[TBL] [Abstract][Full Text] [Related]
55. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.
Cohen JC; Illingworth P
Dev World Bioeth; 2003 May; 3(1):27-48. PubMed ID: 14577451
[TBL] [Abstract][Full Text] [Related]
56. Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals.
Main B; Csanadi M; Ozieranski P
Health Econ Policy Law; 2022 Jul; 17(3):348-365. PubMed ID: 35382921
[TBL] [Abstract][Full Text] [Related]
57. Managed Entry Agreements: Policy Analysis From the European Perspective.
Dabbous M; Chachoua L; Caban A; Toumi M
Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
[TBL] [Abstract][Full Text] [Related]
58. The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy.
Scheijmans FEV; Zomers ML; Fadaei S; Onrust MR; van der Graaf R; Delden JJMV; van der Pol WL; van Thiel GJMW
BMC Health Serv Res; 2022 Nov; 22(1):1320. PubMed ID: 36333803
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]